These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11093891)

  • 1. [Secondary prevention of ischemic heart disease in the Cuidad Real Province, Spain. Effectiveness of lipid-lowering therapy in primary health care].
    Groupo de Investigation del estudio ELIPSE (El Estudio de Lípidos en Prevención Secundaria de Cardiopatía Isquémica)
    Med Clin (Barc); 2000 Sep; 115(9):321-5. PubMed ID: 11093891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suboptimal lipid levels in clinical practice among Portuguese adults with dyslipidemia under lipid-lowering therapy: Data from the DISGEN-LIPID study.
    da Silva PM; Aguiar C; Morais J;
    Rev Port Cardiol (Engl Ed); 2019 Aug; 38(8):559-569. PubMed ID: 31706732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-lowering treatment in hypercholesterolemic patients: the CEPHEUS Thailand survey.
    Sukonthasarn A; Homsanit M; Prommete B; Chotinaiwattarakul C; Piamsomboon C; Likittanasombat K
    J Med Assoc Thai; 2011 Dec; 94(12):1424-34. PubMed ID: 22295727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability among cardiologists in the management of patients under secondary prevention of ischemic heart disease.
    Stein R; Alboim C; Campos C; Mello RB; Rosito GA; Polanczyk CA
    Arq Bras Cardiol; 2004 Sep; 83(3):223-6; 219-22. PubMed ID: 15375470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characterization of lipid profile in primary health care users in Portugal].
    Cortez-Dias N; Robalo Martins S; Belo A; Fiúza M;
    Rev Port Cardiol; 2013 Dec; 32(12):987-96. PubMed ID: 24280078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering drugs in ischaemic heart disease: a quasi-experimental uncontrolled before-and-after study of the effectiveness of clinical practice guidelines.
    Dalmau R; Boira M; Aguilar C; López C; Rodríguez D; Gentille D; Bofill D; Diogene E; Pepió JM
    BMC Cardiovasc Disord; 2011 Aug; 11():47. PubMed ID: 21816068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of long-term cardiac training on lipids concentration in patients with chronic heart ischemic disease treated with simvastatin].
    Kałka D; Sobieszczańska M; Kopka L; Marciniak W; Zawadzka-Bartczak E; Bak A; Popielewicz-Kautz A; Korzeniowska J; Janczak J; Adamus J
    Pol Merkur Lekarski; 2007 Feb; 22(128):101-6. PubMed ID: 17598652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
    J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting.
    Mosca L; Merz NB; Blumenthal RS; Cziraky MJ; Fabunmi RP; Sarawate C; Watson KE; Willey VJ; Stanek EJ
    Circulation; 2005 Feb; 111(4):488-93. PubMed ID: 15687138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
    Bersot TP; Pépin GM; Mahley RW
    Am Heart J; 2003 Dec; 146(6):1052-9. PubMed ID: 14660998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving optimal lipid goals in patients with coronary artery disease.
    Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
    Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy.
    Masana L; Ibarretxe D; Heras M; Cabré A; Ferré R; Merino J; Plana N; Girona J
    Atherosclerosis; 2013 Feb; 226(2):471-5. PubMed ID: 23290265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a pharmacy care management program for veterans with dyslipidemia.
    Smith MC; Boldt AS; Walston CM; Zillich AJ
    Pharmacotherapy; 2013 Jul; 33(7):736-43. PubMed ID: 23625745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.